Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 5,926 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Acute Myeloid Leukemia
Interventions: oral azacitidine (CC-486); Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: PSP - Progressive Supranuclear Palsy
Interventions: LM11A-31, Matching Placebo; Drug
Lead sponsor: Adam Boxer; Other
Eligibility: 41 Years to 86 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lymphoma, Melanoma, Neoplasm Metastasis, Renal Cell Carcinoma
Interventions: COL-3; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: enterade, Pedialyte, Gatorade, Water; Other
Lead sponsor: Sonoma State University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Rohnert Park, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Ortho-Cyclen, Dulaglutide; Drug · Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Solid Tumors, Brain Tumors, Brain Metastases
Interventions: Satraplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 25 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tourette Syndrome
Interventions: SCI-110, Placebo; Drug · Other
Lead sponsor: Neurothera Labs Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Amyotrophic Lateral Sclerosis, Sialorrhea
Interventions: Botulinum toxin type B (Myobloc), Injection of salivary glands; Drug · Procedure
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 21 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: Kansas City, Kansas • Charlotte, North Carolina

Conditions: Lung Cancer, Precancerous Condition, Tobacco Use Disorder
Interventions: calcitriol, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 40 Years to 79 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Acromegaly
Interventions: Octreotide capsules; Drug
Lead sponsor: Chiasma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Xerostomia, Head and Neck Cancer, Xerostomia Following Radiotherapy
Interventions: Remineralizing Extreme Dry Mouth Spray with Xylitol, Alcohol-Free Moisturizing Dry Mouth Spray; Other · Device
Lead sponsor: Jonas Johnson; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Obesity
Interventions: Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes Mellitus, Type 2, Hyperglycemia
Interventions: Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd, Empagliflozin high dose qd, Empagliflozin low dose bid, Empagliflozin high dose bid; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 41
States / cities: Birmingham, Alabama • Manley Hot Springs, Alaska • Glendale, Arizona + 33 more

Conditions: Small Cell Lung Cancer
Interventions: topotecan/cisplatin, etoposide/cisplatin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 66
States / cities: Hoover, Alabama • Chula Vista, California • Fountain Valley, California + 57 more

Conditions: Schizophrenia
Interventions: OPC-34712; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Miami, Florida • Minneapolis, Minnesota • San Antonio, Texas

Conditions: Multiple Sclerosis
Interventions: oral lipoic acid (LA), lipoic acid (LA) with fish oil and LA without fish oil, R lipoic acid; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Dental Plaque
Interventions: 19416-154-1, W002194-0221P; Device
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Spinal Cord Injury
Interventions: extended release beta-2 adrenergic agonist, placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 23
States / cities: Dothan, Alabama • Downey, California • Miami, Florida + 19 more

Conditions: Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma
Interventions: Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 27
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 22 more

Conditions: Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
Interventions: Q702, Pembrolizumab; Drug · Biological
Lead sponsor: Qurient Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Los Angeles, California • Louisville, Kentucky

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Etentamig, Pomalidomide, Daratumumab, Dexamethasone, Carfilzomib, Teclistamab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 24
States / cities: Tucson, Arizona • Cerritos, California • Los Angeles, California + 19 more

Conditions: Ultrasound, Oral Mucosa, Gingival Recession, Alveolar Bone Loss
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Diseases
Interventions: THE-630; Drug
Lead sponsor: Theseus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Miami, Florida + 4 more

Search by objective public record fields.

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31

A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

"Beverage Hydration Index" of Commercial Therapeutic Beverages

A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants

Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

SCI-110 in the Treatment of Tourette Syndrome

Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer

Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

Blinded Dry Mouth Spray Crossover Study

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis

A Four-Week Study to Measure the Effectiveness of an Experimental Mouthwash Used After Teeth Cleaning

Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

Sonographic Imaging of Oral and Dental Anatomical Structures (A Pilot Study)

A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)